Gopal Raghuvanshi

Director

The oncology landscape is evolving at an unprecedented pace. From targeted therapies and immunotherapies to biosimilars and personalized medicine, advance­ments in cancer treatment are continuously reshaping clini­cal practice and improving patient outcomes.

Alongside these breakthroughs, however, comes an equally pressing need for pharmaceutical companies that can ensure consistent prod­uct availability, maintain uncompromising quality standards, and respond quickly to the changing needs of oncologists and patients.

It is within this highly specialized environment that Xantus Pharma is building its presence. Founded by Gopal Raghuvanshi along with ND Sharma with an exclusive focus on oncology, the company is leveraging deep domain expertise to create a differentiated position in one of the pharmaceutical industry's most demanding therapeutic segments.

According to Gopal Raghuvanshi, “The company's focus is not on competing with industry giants through scale alone, but on building scientific credibility, identifying unmet clinical needs, and delivering solutions that improve the overall cancer care experience.”

Built on Deep Oncology Expertise

Although Xantus Pharma is a relatively young organization, its foundation is backed by more than two decades of oncology experience. Before establishing the company, Gopal Raghuvanshi spent over 23 years working exclusively in the oncology segment, building his career across organizations such as Shanta Biotech, Ranbaxy, Sun Pharma Oncology, and another leading oncology company where he served in senior leadership positions for nearly fifteen years.

These experiences gave him a comprehensive understanding of oncology, from physician engagement and product strategy to commercial operations and market development. More importantly, they enabled him to understand the practical challenges faced by oncologists and cancer patients beyond the treatment itself.

“That knowledge ultimately became the driving force behind Xantus Pharma. Rather than diversifying into multiple therapeutic categories, the company chose to dedicate itself entirely to oncology, allowing it to build on established scientific expertise and a deep understanding of the evolving cancer treatment landscape”, shares Gopal.

Identifying Opportunities Beyond Conventional Therapies

For Xantus Pharma, innovation is not limited to introducing new anticancer medicines. The company also recognizes the importance of supportive care, an area that often receives less commercial attention despite playing a critical role in patient outcomes.

Cancer therapies frequently lead to complications such as chemotherapy-induced nausea and vomiting, dry mouth, anorexia & cachexia, Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) and many more. These side effects can significantly affect treatment adherence and patients' quality of life, yet many remain underserved because they fall outside the industry's highest-value product categories.

Raghuvanshi explains that the company's approach begins with continuously studying scientific literature, monitoring treatment guidelines, and engaging with healthcare professionals to identify these unmet needs.

Rather than expanding its portfolio indiscriminately, Xantus Pharma seeks to introduce products that address genuine clinical gaps while supporting oncologists in delivering more comprehensive patient care.

Science-Driven Decision Making

Scientific evidence remains central to the company's product strategy. One example highlighted by Gopal Raghuvanshi is the introduction of Diclofenac Gel for the management of Hand-Foot Syndrome, a painful toxicity associated with certain chemotherapy regimens.

Although Diclofenac is an established medicine, recent clinical evidence published in the Journal of Clinical Oncology demonstrated its effectiveness in preventing this chemotherapy-related complication. Owing to this research, Xantus Pharma introduced the product in a larger pack size designed specifically for oncology patients.

The process required convincing manufacturing partners to support a relatively new clinical indication, a challenge that was overcome through detailed scientific discussions and published evidence.

For the company, this initiative reflects a broader philosophy: innovation is not always about discovering new molecules; it can also come from applying established therapies in clinically meaningful ways supported by robust scientific data.

Delivering Operational Excellence

Reliability is a defining requirement in oncology, where treatment interruptions can directly impact patient care. Xantus Pharma therefore places considerable emphasis on operational planning and quality assurance.

Working with manufacturing partners, the company follows proactive inventory management practices to account for extended production timelines and ensure uninterrupted product availability across its distribution network. Advance planning allows the organization to respond more effectively to market demand while minimizing supply disruptions.

Quality assurance is equally rigorous. Every product batch is supported by Certificates of Analysis and manufacturing documentation, while independent quality verification provides an additional layer of confidence before products reach hospitals, stockists, and healthcare providers.

This disciplined approach reflects the company's commitment to delivering medicines that healthcare professionals can trust, both in terms of quality and timely availability.

A Future Focused on Meaningful Growth

As oncology continues to embrace innovations such as immunotherapies, CAR-T cell therapies, biosimilars, and personalized medicine, Xantus Pharma intends to expand its portfolio in line with emerging scientific developments. However, Raghuvanshi emphasizes that the company's long-term vision extends beyond commercial growth.

Improving the quality of life of cancer patients remains a central objective. While advanced therapies continue to transform survival outcomes, supportive care products that reduce treatment-related complications remain equally important in helping patients navigate their cancer journey.

The company also believes that sustainable success begins with people. Rather than pursuing aggressive revenue targets, Xantus Pharma is focused on building a strong team, creating a supportive work culture, and establishing lasting relationships with healthcare professionals based on scientific integrity and trust.

Although still in the early stages of its journey, Xantus Pharma is laying the foundation for long-term growth by combining deep oncology expertise with evidence-based product development, operational discipline, and an unwavering commitment to patient-centric care.

In a sector where science, reliability, and compassion must work together, the company is steadily positioning itself as a trusted partner in advancing oncology care.